NCT07079670View on ClinicalTrials.gov

Safety and Immunogenicity of NVX-CoV2705

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 16, 2025

Primary Completion Date

April 16, 2026

Study Completion Date

June 16, 2026

Conditions
COVID-19SARS-CoV-2 Infection
Interventions
BIOLOGICAL

NVX-CoV2705

Intramuscular (deltoid) injection at an antigenic dose of 5 µg with 50 µg Matrix-M adjuvant.

Sponsors

Lead Sponsor

Novavax
All Listed Sponsors
lead

Novavax

INDUSTRY

NCT07079670 - Safety and Immunogenicity of NVX-CoV2705 | Biotech Hunter | Biotech Hunter